Joseph R. Berger, MD, looks forward to expanded discussions on the best treatment approaches for neuromyelitis optica spectrum disorders at the upcoming ECTRIMS 2024 meeting, including head-to-head ...
Neuromyelitis optica spectrum disorder (NMOSD) is neuroinflammatory disease characterized by optic neuritis and myelitis with presence of anti-aquaporin-4 (AQP4) antibodies. Satralizumab is an anti-IL ...
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback